Hercules, CA — January 15, 2015 — BioInformatics LLC has recognized Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) with two prestigious Life Science Industry Awards for “Best Protein Expression & Analysis Products” and “Best Workflow Solutions — Genomics.” These annual awards from BioInformatics, a market intelligence provider, recognize the world’s top-performing life science suppliers, as chosen by customers.
BioInformatics announced the winners at a ceremony in Washington, D.C. in November.
“Bio-Rad has long been synonymous with protein analysis,” said Nicole Camara, PhD, senior science advisor at BioInformatics LLC. “But they have been steadily expanding their portfolio of integrated products for genomics researchers, and their more recent focus on Droplet Digital™ PCR (ddPCR™) suggests exciting times ahead for them.”
Bio-Rad’s genomic workflow solutions include PrimePCR™ Assays for real-time PCR and ddPCR, which are expertly designed and experimentally validated for guaranteed performance, and real-rime PCR supermixes that provide robust amplification for even the most challenging templates and target sequences. Bio-Rad also offers real-time PCR detection systems, including CFX Touch Systems that enable researchers to quickly set up runs and monitor amplification traces in real time on an integrated LCD touch screen.
Bio-Rad’s protein expression and analysis solutions include the Bio-Plex® Multiplex System and the V3 Western Workflow™. Bio-Plex immunoassays are built on Luminex xMAP technology and enable the detection and quantification of as many as 500 different protein biomarkers in a single reaction. Bio-Rad’s years of experience with xMAP technology have given the company in-depth knowledge and an understanding of the needs of multiplex users, including their desire for automation and a simplified user experience. The V3 Western Workflow provides researchers with more confidence by creating quality checkpoints — enabled by Bio-Rad’s proprietary stain-free technology — throughout the western workflow. Stain-free technology also underlies stain-free total protein normalization, which has been demonstrated to be more reliable than traditional normalization methods such as using housekeeping proteins.
The Life Science Industry Awards recognize the top life science suppliers in 28 product and service categories. BioInformatics received nominations from more than 5,000 scientific experts in its online community and analyzed the submissions via a quantitative scoring methodology.
“We are honored to be recognized as leaders in both the genomics and protein expression and analysis markets,” said Kate Smith, marketing director of Bio-Rad’s Gene Expression Group. “These Life Science Industry Awards are a reflection of how Bio-Rad strives to develop innovative solutions that provide scientists with the tools to drive their research wherever their imaginations take them.”
For more information about the awards, please visit www.lifescienceindustryawards.com.
About Bio-Rad
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) develops, manufactures, and markets a broad range of innovative products and solutions for the life science research and clinical diagnostic markets. The company is renowned for its commitment to quality and customer service among university and research institutions, hospitals, and public health and commercial laboratories, as well as the biotechnology, pharmaceutical, and food safety industries. Founded in 1952, Bio-Rad is based in Hercules, California, and serves more than 100,000 research and healthcare industry customers through its global network of operations. The company employs approximately 7,800 people worldwide and had revenues exceeding $2.1 billion in 2013. For more information, visit our website at www.bio-rad.com.
This release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements generally can be identified by the use of forward-looking terminology such as, “believe,” “expect,” “may,” “will,” “intend,” “estimate,” “continue,” or similar expressions or the negative of those terms or expressions. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. For further information regarding the Company's risks and uncertainties, please refer to the “Risk Factors” in the Company’s public reports filed with the Securities and Exchange Commission, including the Company’s most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. Bio-Rad Laboratories, Inc., disclaims any obligation to update these forward-looking statements.
For more information contact:
Kate Smith
Bio-Rad
510-741-5307
Kate_Smith@bio-rad.com
Ken Li
Chempetitive Group
312-997-2436 x 112
kli@chempetitive.com